These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 22475049

  • 1. Potency, selectivity and prolonged binding of saxagliptin to DPP4: maintenance of DPP4 inhibition by saxagliptin in vitro and ex vivo when compared to a rapidly-dissociating DPP4 inhibitor.
    Wang A, Dorso C, Kopcho L, Locke G, Langish R, Harstad E, Shipkova P, Marcinkeviciene J, Hamann L, Kirby MS.
    BMC Pharmacol; 2012 Apr 04; 12():2. PubMed ID: 22475049
    [Abstract] [Full Text] [Related]

  • 2. Establishment of a dipeptidyl peptidases (DPP) 8/9 expressing cell model for evaluating the selectivity of DPP4 inhibitors.
    Huan Y, Jiang Q, Liu JL, Shen ZF.
    J Pharmacol Toxicol Methods; 2015 Apr 04; 71():8-12. PubMed ID: 25464020
    [Abstract] [Full Text] [Related]

  • 3. The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo.
    Uchii M, Sakai M, Hotta Y, Saeki S, Kimoto N, Hamaguchi A, Kitayama T, Kunori S.
    J Pharmacol Sci; 2017 Nov 04; 135(3):126-130. PubMed ID: 29113790
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
    Scheen AJ.
    Clin Pharmacokinet; 2010 Sep 04; 49(9):573-88. PubMed ID: 20690781
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O, Kahle M, Deacon CF, Holst JJ, Nauck MA.
    Diabetes Obes Metab; 2016 Nov 04; 18(11):1100-1109. PubMed ID: 27300579
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes.
    Pratley RE, Salsali A.
    Curr Med Res Opin; 2007 Apr 04; 23(4):919-31. PubMed ID: 17407649
    [Abstract] [Full Text] [Related]

  • 12. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL.
    Clin Pharmacokinet; 2012 Mar 01; 51(3):147-62. PubMed ID: 22339447
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
    Thornberry NA, Gallwitz B.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug 01; 23(4):479-86. PubMed ID: 19748065
    [Abstract] [Full Text] [Related]

  • 15. DPP4 inhibitors for diabetes--what next?
    Lambeir AM, Scharpé S, De Meester I.
    Biochem Pharmacol; 2008 Dec 15; 76(12):1637-43. PubMed ID: 18755155
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pharmacological profiles of gemigliptin (LC15-0444), a novel dipeptidyl peptidase-4 inhibitor, in vitro and in vivo.
    Kim SH, Jung E, Yoon MK, Kwon OH, Hwang DM, Kim DW, Kim J, Lee SM, Yim HJ.
    Eur J Pharmacol; 2016 Oct 05; 788():54-64. PubMed ID: 27298192
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.